查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1559915

全球腮腺炎疫苗市场：趋势、预测与竞争分析（~2030）

Mumps Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年，全球腮腺炎疫苗市场规模将达到 11 亿美元，2024 年至 2030 年复合年增长率为 8.6%。市场的主要驱动因素是腮腺炎感染疾病的高盛行率和盛行率、对高效、安全的腮腺炎疫苗的需求不断增长以及政府对腮腺炎疫苗接种计划的支持不断增加。全球腮腺炎疫苗市场的未来可能包括小儿科诊所、医院和非政府组织市场的机会。

预计组合将在预测期内实现最高成长，因为它具有便利性和成本效益等优势。

在这个市场中，由于儿童广泛使用腮腺炎疫苗，小儿科诊所将继续成为最大的市场区隔。

预计北美在预测期内将经历最高的成长。

腮腺炎疫苗市场新动向

腮腺炎疫苗市场的新趋势反映了疫苗技术的变化、保险覆盖力度的增加以及人们对腮腺炎预防意识的增强。

  • 技术进步：配方技术和输送系统的创新有助于提高腮腺炎疫苗的功效和安全性。
  • 提高疫苗接种覆盖率：透过公共卫生宣传活动和纳入常规免疫计画来提高疫苗接种覆盖率，正在提高世界各地腮腺炎预防的有效性。
  • 加强剂量：加强剂量对于维持长期免疫力至关重要，并有助于在疫苗保护作用下降时中和腮腺炎的爆发。
  • 全球卫生措施：近年来，与疫苗取得和疫苗接种率相关的全球卫生措施有所增加，特别是在低收入和中等收入国家。
  • 解决疫苗抗药性：将加强公众教育和沟通，以解决疫苗犹豫问题并提高接种率。

这将成为腮腺炎疫苗市场变化的关键驱动力，疫苗功效随着覆盖范围和整体公共卫生反应的增加而提高。

腮腺炎疫苗市场近期趋势

腮腺炎疫苗市场的开拓重点在于改善疫苗、改变政策、扩大疫苗接种覆盖率。

  • 开发改良的疫苗配方 为疫苗开发的新配方旨在提高安全性和有效性，并提高对流行性腮腺炎感染併发症的保护。
  • 加强剂的新优先事项：在时间表中添加加强剂也将有助于减少诸如人群免疫力减弱和最近流行性腮腺炎死灰復燃等问题。
  • 扩大免疫规划：将腮腺炎疫苗纳入常规免疫规划的努力正在加强努力，特别是在贫困地区和低收入国家。
  • 改善疫苗监测：改善监测和监测系统可以有效追踪腮腺炎病例和疫苗有效性，为实证公共卫生应对措施提供资讯。
  • 全球卫生：全球卫生合作和倡议正在将重点转向确保疫苗的取得和覆盖率，特别是在世界上覆盖率仍然较低的地区。

这将提高腮腺炎疫苗接种计划的效率和覆盖范围，并改善全球感染控制。

腮腺炎疫苗市场的策略性成长机会

腮腺炎疫苗市场的策略性成长机会包括疫苗需求的增加、免疫计画的扩大和技术进步。

  • 常规免疫计画：将流行性腮腺炎疫苗纳入常规免疫计画将提高感染率和幼儿期保护，创造成长机会。
  • 加强计画：进一步实施和扩大加强计画可以解决免疫力下降的问题，并改善对流行性腮腺炎的长期保护。
  • 公共卫生宣传活动：扩大公共卫生宣传活动以意识提升并克服对疫苗接种的犹豫不决，有可能提高疫苗接种覆盖率并减少感染疾病的发生率。
  • 全球卫生伙伴关係：与全球卫生伙伴的合作将有助于扩大低收入和中等收入国家疫苗取得和分配的范围和公平性。预计这将扩大市场并进一步改善全球健康。
  • 创新：对新疫苗技术和输送系统的投资为提高疫苗功效和安全性提供了新的可能性，从而提高了疫苗的市场接受度。

所有这些策略机会都将改善腮腺炎疫苗的取得、功效和覆盖范围，推动市场成长。

腮腺炎疫苗市场的驱动因素与挑战

各种技术、经济和监管因素正在影响腮腺炎疫苗市场，其中包括驱动因素和挑战因素。

推动腮腺炎疫苗市场的因素包括：

1. 技术进步：创新疫苗和输送系统的开发正在提高疫苗安全性和有效性的标准，并推动市场发展。

2. 提高疫苗接种意识：提高腮腺炎疫苗接种意识导致疫苗接种率提高。

3. 政府政策：有利的政府政策和疫苗接种计画的拨款正在促进疫苗的取得并刺激市场的进一步成长。

4. 全球健康倡议：国际伙伴关係和卫生倡议正在帮助改善疫苗的供应和获取，特别是在资源匮乏的环境中。

腮腺炎疫苗市场的挑战包括：

1. 疫苗供应挑战：供应链中断会严重影响疫苗的供应和获取，进而影响疫苗接种计划，最终影响市场稳定。

2. 疫苗分发挑战：与疫苗分发相关的后勤挑战，特别是在偏远地区，是有效免疫和市场成长的主要障碍。

3. 确保法规遵循：法规要求的复杂性可能很困难，并且会影响市场准入和产品可用性。

这些市场驱动因素和挑战将透过对疫苗开发、疫苗接种率和整体公共卫生的影响来影响腮腺炎疫苗市场的形成。

腮腺炎疫苗按市场

这项研究按产品类型、年龄层、最终用途和地区对全球腮腺炎疫苗进行了预测。

各国腮腺炎疫苗市场前景

疫苗技术的进步、当地卫生政策和不断兴起的全球卫生措施正在推动腮腺炎疫苗市场的近期发展。

  • 美国：为了应对该国最近爆发的疫情，该国在疫苗配方和加强剂量的使用方面取得了进展。我们也正在改进监测和疫苗宣传活动，以阻止疫苗接种覆盖率下降，从而阻止腮腺炎病毒感染疾病的死灰復燃。
  • 中国：扩大腮腺炎免疫规划，纳入一般免疫规划。人们也非常关注提高农村地区的疫苗接种率并透过公共教育减少疫苗犹豫。
  • 德国：制定新的疫苗接种指南并改善疫苗的获取，制定更广泛的腮腺炎控制策略。透过公共卫生宣传活动确保充足的疫苗接种也是该国面临的关键挑战。
  • 印度：随着印度希望将疫苗接种活动覆盖到最贫困地区的更多地区，该市场正在持续成长。正在继续努力将腮腺炎疫苗纳入国家免疫规划，并改善疫苗运输的物流。
  • 日本：日本修订了疫苗接种指南，建议加强接种腮腺炎疫苗。日本也正在加强其疫苗监测系统，以便更好地监测腮腺炎发生率和疫苗有效性。

常问问题

Q.1 腮腺炎疫苗的市场规模有多大？

A1. 预计到 2030 年，全球腮腺炎疫苗市场将达到 11 亿美元。

Q.2 腮腺炎疫苗市场的成长预测如何？

A2. 预计 2024 年至 2030 年全球腮腺炎疫苗市场将以 8.6% 的复合年增长率成长。

Q.3 影响腮腺炎疫苗市场成长的关键驱动因素有哪些？

A3. 该市场的主要驱动因素是腮腺炎感染的高盛行率和发病率、对高效和安全的腮腺炎疫苗的需求不断增长以及政府对腮腺炎疫苗接种计划的支持不断增加。

Q4.市场的主要细分市场是：

A4. 腮腺炎疫苗市场前景广阔，小儿科诊所、医院和非政府组织市场都有机会。

Q5.市场的主要企业是：

A5.主要企业如下：

  • MedImmune
  • Johnson & Johnson
  • Merck
  • Sanofi
  • Serum Institute of India
  • Bavarian Nordic
  • Astellas Pharma India
  • CSL
  • Emergent BioSolutions
  • GlaxoSmithKline

Q6.未来最大的细分市场是什么？

A6.我们预计，由于其便利性和成本效益等优势，组合将在预测期内达到最高成长。

Q7. 未来五年预计哪些地区的市场成长最大？

A7. 预计北美地区在预测期内将出现最高成长。

Q8. 可以客製化报告吗？

A8. 是的，我们提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球腮腺炎疫苗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球腮腺炎疫苗市场趋势（2018-2023）与预测（2024-2030）
  • 全球腮腺炎疫苗市场：依产品类型
    • 单价
    • 组合
    • 二价
    • 三价
    • 其他的
  • 全球腮腺炎疫苗市场：依年龄层划分
    • 儿科的
    • 成人
  • 全球腮腺炎疫苗市场：依最终用途分类
    • 小儿科诊所
    • 医院
    • NGO
    • 其他的

第 4 章 2018-2030 年按地区分類的市场趋势与预测分析

  • 全球腮腺炎疫苗市场：依地区
  • 北美腮腺炎疫苗市场
  • 欧洲腮腺炎疫苗市场
  • 亚太地区流行性腮腺炎疫苗市场
  • 其他地区腮腺炎疫苗市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 依产品类型
    • 按年龄组别
    • 按最终用途
    • 按地区
  • 全球腮腺炎疫苗市场新趋势
  • 战略分析
    • 新产品开发
    • 全球腮腺炎疫苗市场产能扩张
    • 全球腮腺炎疫苗市场的併购和合资企业
    • 认证和许可

第七章主要企业概况

  • MedImmune
  • Johnson & Johnson
  • Merck
  • Sanofi
  • Serum Institute of India
  • Bavarian Nordic
  • Astellas Pharma India
  • CSL
  • Emergent BioSolutions
  • GlaxoSmithKline
简介目录

Mumps Vaccine Trends and Forecast

The future of the global mumps vaccine market looks promising with opportunities in the pediatric clinic, hospital, and NGO markets. The global mumps vaccine market is expected to reach an estimated $1.1 billion by 2030 with a CAGR of 8.6% from 2024 to 2030. The major drivers for this market are high prevalence and morbidity of mumps infection, growing demand for efficient and safe mumps vaccines, and rising government support for mumps vaccination programs.

Lucintel forecasts that combinational is expected to witness highest growth over the forecast period due to its advantages like convenience and cost-effectiveness.

Within this market, pediatric clinic will remain the largest segment due to significant application of mumps vaccine among children.

North America is expected to witness highest growth over the forecast period.

Emerging Trends in the Mumps Vaccine Market

Developing trends in the mumps vaccine market are testament to changing vaccine technology, increasing coverage efforts, and growing awareness about the prevention of mumps.

  • Technological Advancement: Innovations in the technology of formulation and delivery systems contribute to enhancing the efficacy and safety profiles of the vaccines against mumps.
  • Increased Vaccination Coverage: Increased vaccination coverage through public health campaigns and integration into routine immunization programs has been expanding protection against mumps across the globe.
  • Booster Doses: Increasingly, there is emphasis on booster doses, which are very crucial for long-term immunity and help neutralize mumps outbreaks associated with waning vaccine protection.
  • Global Health Initiatives: Global health initiatives of collaboration on access to and coverage of vaccines have increased in recent years, particularly for low- and middle-income countries.
  • Addressing Vaccine Hesitancy: Public education and communication are enhanced to address vaccine hesitancy and improve vaccination rates.

This in turn would act as a key driver of change within the mumps vaccine market, where the efficacy of the vaccines would increase, along with coverage and the overall public health response.

Recent Developments in the Mumps Vaccine Market

The development in the mumps vaccine market is focused on improving vaccines, policy changes, and the expansion of vaccination.

  • Development of Improved Vaccine Formulations: New formulations developed for vaccines are intended to enhance their safety and efficacy profiles, enabling their improved protective function against complications due to mumps infections.
  • Booster Doses a New Priority: Booster doses added to the schedules will also keep such issues at bay as waning immunity of populations and recent resurgences of mumps outbreaks.
  • Expansion of Immunization Programs: There is increased effort toward integrating the mumps vaccine into routine immunization programs, especially in most deprived areas and low-income countries.
  • Improved Vaccine Surveillance: With this, the improvement in monitoring and surveillance systems enables the effective tracking of cases and the effectiveness of vaccines against the disease to inform evidence-based public health responses.
  • Global Health: Global health collaborations and initiatives have shifted focus toward ensuring access to and coverage of vaccines, particularly in those areas of the world where vaccination rates remain low.

Accordingly, the improvements described enhance the efficiency and coverage of mumps vaccination programs, thus improving global control of the infection.

Strategic Growth Opportunities for Mumps Vaccine Market

The strategic growth opportunities in the mumps vaccine market include an increasing demand for vaccines, expanded immunization programs, and technological advancements.

  • Routine Immunization Programs: The expanding mumps vaccine into routine immunization programs creates growth opportunities through increased coverage and protection from early childhood onwards.
  • Booster Dose Programs: Increased implementation and expansion of booster dose programs can help to address issues of waning immunity and improve long-term protection against mumps.
  • Public Health Campaigns: Expanding the sphere of public health campaigns toward creating awareness and overcoming vaccine hesitancy will present potential ways to increase vaccination rates, hence lowering the rate of infectious diseases.
  • Global Health Partnerships: Collaboration with global health partners may be helpful in extending the reach and equity of vaccine access and distribution in low- and middle-income countries. This will likely ensure market growth and further global health improvement.
  • Technological Innovations: Investment in new vaccine technologies and delivery systems offers new possibilities to improve vaccine efficacy and safety, leading to wider market acceptance of the vaccines.

All these strategic opportunities enhance access, efficacy, and coverage for mumps vaccines, thus driving market growth.

Mumps Vaccine Market Driver and Challenges

Various technological, economic, and regulatory factors are affecting the mumps vaccines market, which includes both driving and challenging factors.

The factors responsible for driving the mumps vaccine market include:

1. Technological Advancement: The development of new innovative vaccines and delivery systems raises the bar on vaccine safety and efficacy, thereby driving the market.

2. Increased Vaccination Awareness: Increasing awareness toward vaccination against mumps diseases is leading to a rise in vaccination rates.

3. Government Policies: Favorable government policies and allocations toward vaccination programs spur the market to grow further, easing access to the vaccines.

4. Global Health Initiative: International collaborations and health initiatives help improve vaccine availability and access, particularly within resource-poor settings

Challenges in the mumps vaccine market are:

1. Vaccine Supply Challenges: Disruptions in supply chains seriously affect the availability and access to vaccines, thus impacting vaccination programs and ultimately market stability.

2. Vaccine Distribution Challenges: Logistical challenges related to vaccine distribution, particularly in far-flung areas, act as a major hindrance toward effective immunization and market growth.

3. Ensuring Regulatory Compliance: The complexity of regulatory requirements is challenging and may impact market entry and product availability.

These drivers and challenges influence the shaping of the mumps vaccine market by their effect on vaccine development, coverage, and overall public health outcomes.

List of Mumps Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies mumps vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the mumps vaccine companies profiled in this report include-

  • MedImmune
  • Johnson & Johnson
  • Merck
  • Sanofi
  • Serum Institute of India
  • Bavarian Nordic
  • Astellas Pharma India
  • CSL
  • Emergent BioSolutions
  • GlaxoSmithKline

Mumps Vaccine by Segment

The study includes a forecast for the global mumps vaccine by product type, age group, end use, and region.

Mumps Vaccine Market by Product Type [Analysis by Value from 2018 to 2030]:

  • Monovalent
  • Combinational
  • Divalent
  • Trivalent
  • Others

Mumps Vaccine Market by Age Group [Analysis by Value from 2018 to 2030]:

  • Pediatric
  • Adult

Mumps Vaccine Market by End Use [Analysis by Value from 2018 to 2030]:

  • Pediatric Clinic
  • Hospitals
  • NGOs
  • Others

Mumps Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Mumps Vaccine Market

The advancement of vaccine technology, regional health policies, and growing global health initiatives are driving development in the recent mumps vaccine market.

  • United States: The country has recorded developments in relation to advancements in the formulation of vaccines and the uptake of booster doses as a response to the outbreaks recorded in the country lately. It is also putting in place an improved monitoring and vaccination campaign to try and stem the decline in vaccine coverage that contributes to the resurgence of the mumps virus infection.
  • China expanded the mumps vaccination program by incorporating it into the general immunization program. Much attention is also paid to the improvement of vaccine coverage in rural areas and vaccination hesitancy through public education.
  • Germany designed new vaccination guidelines and increased accessibility to vaccines within the broader strategy to control mumps. Another significant task for this country is to ensure adequate vaccinations by promoting public health campaigns.
  • India: The mumps vaccine market is growing continuously as India tries to cover more and more ground in terms of vaccination outreach in its most under-resourced areas. There are continuing activities aimed at the integration of the mumps vaccine into the national immunization schedule, while the improvement of logistics regarding vaccine delivery is also being pursued.
  • Japan: Japan has revised its guidelines for vaccination by recommending booster doses of the mumps vaccine. Japan is also strengthening surveillance systems for vaccines in order to monitor better the incidence of the disease and effective performance of vaccines.

Features of the Global Mumps Vaccine Market

Market Size Estimates: Mumps vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Mumps vaccine market size by product type, age group, end use, and region in terms of value ($B).

Regional Analysis: Mumps vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, age groups, end uses, and regions for the mumps vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the mumps vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the mumps vaccine market size?

Answer: The global mumps vaccine market is expected to reach an estimated $1.1 billion by 2030.

Q.2 What is the growth forecast for mumps vaccine market?

Answer: The global mumps vaccine market is expected to grow with a CAGR of 8.6% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the mumps vaccine market?

Answer: The major drivers for this market are high prevalence and morbidity of mumps infection, growing demand for efficient and safe mumps vaccines, and rising government support for mumps vaccination programs.

Q4. What are the major segments for mumps vaccine market?

Answer: The future of the mumps vaccine market looks promising with opportunities in the pediatric clinic, hospital, and NGO markets.

Q5. Who are the key mumps vaccine market companies?

Answer: Some of the key mumps vaccine companies are as follows:

  • MedImmune
  • Johnson & Johnson
  • Merck
  • Sanofi
  • Serum Institute of India
  • Bavarian Nordic
  • Astellas Pharma India
  • CSL
  • Emergent BioSolutions
  • GlaxoSmithKline

Q6. Which mumps vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that combinational is expected to witness highest growth over the forecast period due to its advantages like convenience and cost-effectiveness.

Q7. In mumps vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the mumps vaccine market by product type (monovalent, combinational, divalent, trivalent, and others), age group (pediatric and adult), end use (pediatric clinic, hospitals, NGOs, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
  • Market Report

Table of Contents

1. Executive Summary

2. Global Mumps Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Mumps Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Mumps Vaccine Market by Product Type
    • 3.3.1: Monovalent
    • 3.3.2: Combinational
    • 3.3.3: Divalent
    • 3.3.4: Trivalent
    • 3.3.5: Others
  • 3.4: Global Mumps Vaccine Market by Age Group
    • 3.4.1: Pediatric
    • 3.4.2: Adult
  • 3.5: Global Mumps Vaccine Market by End Use
    • 3.5.1: Pediatric Clinic
    • 3.5.2: Hospitals
    • 3.5.3: NGOs
    • 3.5.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Mumps Vaccine Market by Region
  • 4.2: North American Mumps Vaccine Market
    • 4.2.1: North American Mumps Vaccine Market by Product Type: Monovalent, Combinational, Divalent, Trivalent, and Others
    • 4.2.2: North American Mumps Vaccine Market by End Use: Pediatric Clinic, Hospitals, NGOs, and Others
  • 4.3: European Mumps Vaccine Market
    • 4.3.1: European Mumps Vaccine Market by Product Type: Monovalent, Combinational, Divalent, Trivalent, and Others
    • 4.3.2: European Mumps Vaccine Market by End Use: Pediatric Clinic, Hospitals, NGOs, and Others
  • 4.4: APAC Mumps Vaccine Market
    • 4.4.1: APAC Mumps Vaccine Market by Product Type: Monovalent, Combinational, Divalent, Trivalent, and Others
    • 4.4.2: APAC Mumps Vaccine Market by End Use: Pediatric Clinic, Hospitals, NGOs, and Others
  • 4.5: ROW Mumps Vaccine Market
    • 4.5.1: ROW Mumps Vaccine Market by Product Type: Monovalent, Combinational, Divalent, Trivalent, and Others
    • 4.5.2: ROW Mumps Vaccine Market by End Use: Pediatric Clinic, Hospitals, NGOs, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Mumps Vaccine Market by Product Type
    • 6.1.2: Growth Opportunities for the Global Mumps Vaccine Market by Age Group
    • 6.1.3: Growth Opportunities for the Global Mumps Vaccine Market by End Use
    • 6.1.4: Growth Opportunities for the Global Mumps Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Mumps Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Mumps Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Mumps Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: MedImmune
  • 7.2: Johnson & Johnson
  • 7.3: Merck
  • 7.4: Sanofi
  • 7.5: Serum Institute of India
  • 7.6: Bavarian Nordic
  • 7.7: Astellas Pharma India
  • 7.8: CSL
  • 7.9: Emergent BioSolutions
  • 7.10: GlaxoSmithKline